The latest price target for vTv Therapeutics (NASDAQ:VTVT) was reported by HC Wainwright & Co. on March 7, 2023. The analyst firm set a price target for $6.00 expecting VTVT to fall to within 12 months (a possible -61.06% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for vTv Therapeutics (NASDAQ:VTVT) was provided by HC Wainwright & Co., and vTv Therapeutics reiterated their buy rating.

There is no last upgrade for vTv Therapeutics

There is no last downgrade for vTv Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of vTv Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for vTv Therapeutics was filed on March 7, 2023 so you should expect the next rating to be made available sometime around March 7, 2024.

While ratings are subjective and will change, the latest vTv Therapeutics (VTVT) rating was a reiterated with a price target of $0.00 to $6.00. The current price vTv Therapeutics (VTVT) is trading at is $15.41, which is out of the analyst’s predicted range.